Glenmark’s US arm recalling affected lot of Diltiazem Hydrochloride extended-release capsules

16 Dec 2024 Evaluate

Glenmark Pharmaceuticals’ US-based subsidiary -- Glenmark Pharmaceuticals Inc is recalling the affected lot of Diltiazem Hydrochloride extended-release capsules in the US market due to cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit. Diltiazem Hydrochloride extended-release capsules are used to treat high blood pressure. The company initiated the Class II nationwide (US) recall on November 1, 2024.

Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. 


Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×